Mar 24
Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1 - Research
Background: High-risk ALK-mutant neuroblastoma (NB) presents challenges due to drug resistance and an immunosuppressive tumour microenvironment (TME). Combining molecular targeted therapy with adoptive cell therapy offers a potential therapeutic strategy. Objective: To investigate the effects of alectinib, an ALK inhibitor, with disialoganglioside 2 (GD2) chimeric antigen receptor T (CAR-T)…
#Akimasa Tomida#Alectinib#ALKmutated#Antigen#antitumor#boosts#Cells#chimeric#deathligand#disialoganglioside#doi:10.1038/s41416-026-03363-8#efficacy#MEDLINE#National Center for Biotechnology Information#National Institutes of Health#National Library of Medicine#NCBI#neuroblastoma#NIH#NLM#pmid:41866626#Programmed#PubMed Abstract#receptor#research#suppressing#Tomoko Iehara#Yuya Sugitatsu
